The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia
The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia
复制标题
DOI：
10.1038/gim.2013.66
复制
发表时间：
2014-01-01
影响因子：
8.8
通讯作者：
Faughnan, Marie E.
中科院分区：
文献类型：
--
作者：
Grosse, Scott D.;Boulet, Sheree L.;Faughnan, Marie E.
目的：评估美国医疗保险数据在监测遗传性出血性毛细血管扩张症中的作用。遗传性出血性毛细血管扩张症是一种常染色体显性血管疾病，估计患病率为每10,000人中有1.5-2.0人。方法：我们使用2005年至2010年的MarketScan Research数据库来识别拥有雇主赞助的医疗保险和国际疾病分类第9版的个人，临床修改代码为448.0，出现在一次住院索赔或相隔30天的两次门诊索赔中，以定义遗传性出血性毛细血管扩张。我们检查了遗传性出血性毛细血管扩张症患者和普通人群中遗传性出血性毛细血管扩张症并发症的国际疾病分类第9版临床修改代码的频率，以确定与遗传性出血性毛细血管扩张相关的代码组合。结果：排除一个州的观察，遗传性出血性毛细血管扩张症的平均患病率为0.3/10,000人。报告的患病率随着年龄的增长而上升，从相似的每10,000人中有0.1人
Purpose: To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5-2.0 per 10,000 persons worldwide.Methods: We used 2005-2010 MarketScan Research Databases to identify individuals with employer-sponsored health insurance and International Classification of Disease, 9th Revision, Clinical Modification codes of 448.0 present in either one inpatient claim or two outpatient claims 30 days apart to define hereditary hemorrhagic telangiectasia. We examined frequencies of International Classification of Disease, 9th Revision, Clinical Modification codes for conditions that are complications of hereditary hemorrhagic telangiectasia among individuals with hereditary hemorrhagic telangiectasia and the general population to identify combinations of codes associated with hereditary hemorrhagic telangiectasia.Results: Excluding observations from one state, the average prevalence of hereditary hemorrhagic telangiectasia was 0.3 per 10,000 persons. The reported prevalence rose with age from similar to 0.1 per 10,000 at ages